Clinical proof of concept study of APO010 in patients with multiple myeloma

Trial Profile

Clinical proof of concept study of APO010 in patients with multiple myeloma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 31 May 2017

At a glance

  • Drugs APO 010 (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Proof of concept
  • Most Recent Events

    • 31 May 2017 Status changed from planning to recruiting according to a Medical Prognosis Institute media release.
    • 31 May 2017 According to a Medical Prognosis Institute media release, the first patient has entered this trial.
    • 19 May 2017 According to an Oncology Venture media release, screening to identify patients sensitive to immuno-oncology drug APO010 is ongoing at four medical centers and the company expects to initiate this study during May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top